Wellthy Therapeutics is a digital therapeutics company that uses artificial intelligence (AI) and patient centric design to improve patient outcomes for all stakeholders in diabetes care. Its goal is to facilitate behaviour change and self-management for patients, while helping physicians to enable continual care using technology and has commercialized a digital therapeutic for patients with type 2 diabetes, that is the first digital diabetes intervention endorsed by Asia's largest Diabetes Association (RSSDI) as a prescription grade intervention. Wellthy's clinical pilots and early data have proven better diabetes outcomes than any entry level prescription diabetes drug in the world, and it has a proven record of publishing clinical evidence. It recently published real world data at the RSSDI 44th Annual conference in Hyderabad, India, at the AACE 26th Annual Congress in Austin, TX, and at ADA 77th Scientific Sessions in San Diego, CA.
Stage of venture
Years in business4